CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology

CoV-RBD121-NP Vaccine Candidate Protects against Symptomatic Disease following SARS-CoV-2 Challenge in K18-hACE2 Mice and Induces Protective Responses That Prevent COVID-19-Associated Immunopathology

We developed a SARS-CoV-2 vaccine candidate (CoV-RBD121-NP) comprised of a tobacco mosaic virus-like nanoparticle conjugated to the receptor-binding domain of the spike glycoprotein of SARS-CoV-2 fused to a human IgG1 Fc domain. CoV-RBD121-NP elicits strong antibody responses in C57BL/6 mice and is...

Full description

Saved in:
Bibliographic Details
Main Authors: Jennifer K. DeMarco, Joshua M. Royal, William E. Severson, Jon D. Gabbard, Steve Hume, Josh Morton, Kelsi Swope, Carrie A. Simpson, John W. Shepherd, Barry Bratcher, Kenneth E. Palmer, Gregory P. Pogue
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
SARS-CoV-2
COVID-19
betacoronavirus
vaccine
betacoronaviridae
TMV
Medicine
R
Online Access:https://doaj.org/article/d948abd924354895b2c5b1c46d082bd9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/d948abd924354895b2c5b1c46d082bd9

Similar Items